FDA mifepristone safety review delay

Description The FDA has delayed completion of its safety review of mifepristone, leaving a new federal determination pending until March. Overview Medical practitioners are waiting for the FDA to complete a federal safety determination for mifepristone, a medication used in abortions. The agency said it will not finish the review… Read more